Floatz logo

Pevonedistat

Intrahepatic Cholangiocarcinoma

National Cancer Institute (NCI)UNKNOWNPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

38 Active assets in the Intrahepatic Cholangiocarcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Virogin Biotech Canada Ltd
Phase 2BB
Durvalumab
West China Hospital
Phase 2BB
Cis-Diamminedichloroplatinum Ii
Shanghai 6th People's Hospital
Phase 2BB
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3B
Atezolizumab
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Pevonedistat is also rated in:

chronic myelomonocytic leukemiaActive
BB
Indicative · Phase 3
70 / 100
View asset →
acute myeloid leukemiaActive
BB
Indicative · Phase 3
66 / 100
View asset →
myelodysplastic syndromeActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →